France’s pharmaceutical company Sanofi will buy biotech company Synthorx.
Sanofi will pay $68 cash a share, or $2.5 billion for the acquisition. Synthorx is focused on treating cancer and autoimmune disorders.
The deal, expected to close in the first quarter next year, is expected to boost Sanofi’s immuno-oncology portfolio, as indicated by the company.
In a separate announcement, Sanofi revealed that its Sanofi Pasteur global vaccines unit entered a $226 million collaboration with the U.S. Department of Health and Human Services, to increase the company’s domestic pandemic influenza vaccine production capabilities at its Swiftwater, Pa., plant.
The 10-day moving average for SNY crossed bullishly above the 50-day moving average on March 27, 2024. This indicates that the trend has shifted higher and could be considered a buy signal. In of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on March 25, 2024. You may want to consider a long position or call options on SNY as a result. In of 102 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for SNY just turned positive on February 21, 2024. Looking at past instances where SNY's MACD turned positive, the stock continued to rise in of 52 cases over the following month. The odds of a continued upward trend are .
SNY moved above its 50-day moving average on March 25, 2024 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where SNY advanced for three days, in of 311 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SNY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
SNY broke above its upper Bollinger Band on March 25, 2024. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for SNY entered a downward trend on February 23, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.542) is normal, around the industry mean (5.792). P/E Ratio (21.269) is within average values for comparable stocks, (49.793). Projected Growth (PEG Ratio) (0.888) is also within normal values, averaging (3.057). Dividend Yield (0.038) settles around the average of (0.029) among similar stocks. P/S Ratio (2.474) is also within normal values, averaging (3.723).
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 71, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. SNY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a producer of pharmaceutical products
Industry PharmaceuticalsMajor